For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Restructuring | - | -68,000 | -172,000 | 3,471,000 |
| Research and development | 31,454,000 | 29,347,000 | 34,068,000 | 42,658,000 |
| General and administrative | 17,057,000 | 14,684,000 | 18,351,000 | 25,020,000 |
| Total operating expenses | 48,511,000 | 43,963,000 | 52,247,000 | 71,149,000 |
| Loss from operations | -48,511,000 | -43,963,000 | -52,247,000 | -71,149,000 |
| Interest expense | 473,000 | 473,000 | 473,000 | 473,000 |
| Interest and other income, net | 161,000 | 690,000 | 709,000 | 483,000 |
| Accretion of discount on investments, net | 1,229,000 | 1,208,000 | 1,679,000 | 2,220,000 |
| Net loss | -47,594,000 | -42,538,000 | -50,332,000 | -68,919,000 |
| Basic EPS | -0.42 | -0.38 | -0.45 | -0.62 |
| Diluted EPS | -0.42 | -0.38 | -0.45 | -0.62 |
| Basic Average Shares | 112,134,059 | 111,810,836 | 111,571,136 | 111,019,647 |
| Diluted Average Shares | 112,134,059 | 111,810,836 | 111,571,136 | 111,019,647 |
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)